Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GERN

Geron Corp.

Apr 18 • 10:22AM ET

3.72

Dollar change +0.04
Percentage change 1.22	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF PJP IBB IWO SCHA LABU VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.32	Insider Own	17.92%	Shs Outstand	544.91M	Perf Week	-1.19%
Market Cap	2.19B	Forward P/E	-	EPS next Y	-0.12	Insider Trans	0.00%	Shs Float	482.67M	Perf Month	14.26%
Income	-184.13M	PEG	-	EPS next Q	-0.10	Inst Own	51.18%	Short Float	9.67%	Perf Quarter	94.01%
Sales	0.24M	P/S	9127.18	EPS this Y	-1.56%	Inst Trans	-1.67%	Short Ratio	3.75	Perf Half Y	96.05%
Book/sh	0.46	P/B	8.19	EPS next Y	63.59%	ROA	-62.99%	Short Interest	46.66M	Perf Year	81.71%
Cash/sh	0.57	P/C	6.54	EPS next 5Y	5.00%	ROE	-112.29%	52W Range	1.64 - 4.05	Perf YTD	76.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.08%	ROI	-64.38%	52W High	-8.02%	Beta	0.57
Dividend TTM	-	Quick Ratio	3.16	Sales past 5Y	46.26%	Gross Margin	-	52W Low	127.13%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	3.16	EPS Y/Y TTM	11.31%	Oper. Margin	-81832.91%	RSI (14)	66.71	Volatility	8.45% 6.62%
Employees	141	Debt/Eq	0.35	Sales Y/Y TTM	-60.23%	Profit Margin	-77691.14%	Recom	1.17	Target Price	5.08
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	16.36%	Payout	-	Rel Volume	0.44	Prev Close	3.68
Sales Surprise	-71.78%	EPS Surprise	14.29%	Sales Q/Q	-77.67%	Earnings	Feb 28 BMO	Avg Volume	12.46M	Price	3.72
SMA20	10.24%	SMA50	40.91%	SMA200	56.69%	Trades		Volume	973,747	Change	1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Reiterated	Needham	Buy	$4 → $5
Sep-12-23	Upgrade	Goldman	Neutral → Buy	$4
Mar-28-23	Initiated	Goldman	Neutral	$3
Oct-28-22	Initiated	Wedbush	Outperform	$5
Jul-28-22	Resumed	B. Riley Securities	Buy	$4
Nov-02-21	Initiated	Robert W. Baird	Outperform	$4
Feb-18-21	Resumed	B. Riley Securities	Buy	$4
Aug-03-20	Initiated	Stifel	Buy	$3
Nov-19-19	Resumed	B. Riley FBR	Buy	$4
Sep-03-19	Initiated	H.C. Wainwright	Buy	$4
Aug-15-19	Initiated	Cantor Fitzgerald	Overweight	$4
Apr-09-19	Upgrade	Needham	Hold → Buy	$3
Jan-31-19	Upgrade	B. Riley FBR	Neutral → Buy	$1.50 → $3.25
Oct-02-18	Downgrade	B. Riley FBR	Buy → Neutral	$5.75 → $1.50
Jul-05-18	Initiated	B. Riley FBR, Inc.	Buy	$5.75
Sep-13-16	Reiterated	FBR Capital	Outperform	$6 → $5
Sep-13-16	Reiterated	FBR & Co.	Outperform	$6 → $5
Dec-07-15	Reiterated	Piper Jaffray	Overweight	$5 → $10
Apr-21-15	Initiated	Oppenheimer	Outperform	$5.50
Jun-12-14	Upgrade	MLV & Co	Hold → Buy	$2 → $4.25

Show Previous Ratings

Apr-03-24 04:30PM	Geron to Participate at Upcoming Investor Conferences in April (Business Wire)
Mar-19-24 09:07AM	Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Mar-15-24 03:50PM	Geron, Madrigal Pharmaceuticals jump on good news from FDA (Yahoo Finance Video) +92.00%
01:29PM	Stocks to Watch Friday: Adobe, Ulta, Fisker (The Wall Street Journal)
10:47AM	Why Is Geron (GERN) Stock Up 94% Today? (InvestorPlace)
08:57AM	Loading…
08:57AM	Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up (Zacks)
05:00AM	Geron triumphs in FDA AdComm battle, securing 12-2 vote in favor of blood cancer drug imetelstat (FierceBiotech.com)
Mar-14-24 03:54PM	Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS (Business Wire)
Mar-13-24 10:48AM	Implied Volatility Surging for Geron (GERN) Stock Options (Zacks) -6.91%
Mar-12-24 12:28PM	Geron faces uphill battle at FDA meeting, as agency questions benefit-risk profile of imetelstat (FierceBiotech.com) -12.15%
Mar-08-24 04:20PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +7.14%
Feb-28-24 07:05AM	Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -5.57%
Feb-22-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-14-24 04:30PM	Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (Business Wire)
Jan-18-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Loading…
Jan-12-24 08:30AM	Geron to Participate in the B. Riley Securities Virtual Oncology Conference (Business Wire)
Dec-21-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-23 04:15PM	Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS (Business Wire) -6.76%
Dec-06-23 08:00AM	Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis (Business Wire)
Dec-04-23 05:00AM	Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS (Business Wire) -6.53%
Nov-28-23 08:00AM	Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors (Business Wire)
Nov-16-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-23 04:30PM	Geron to Participate at Upcoming Investor Conferences in November (Business Wire)
Nov-02-23 09:00AM	Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS (Business Wire) -7.77%
08:00AM	Geron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 04:30PM	Geron to Announce Third Quarter 2023 Financial Results on November 2, 2023 (Business Wire)
Oct-19-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-12-23 03:26PM	Buy These 2 Beaten-Down Stocks, Goldman Sachs Says, Forecasting up to 130% Upside (TipRanks) -5.41%
Sep-29-23 08:00AM	Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS (Business Wire)
Sep-11-23 04:30PM	Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer (Business Wire)
08:00AM	Loading…
Sep-07-23 08:00AM	Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting (Business Wire)
Sep-05-23 04:30PM	Geron to Participate in the Baird 2023 Global Healthcare Conference (Business Wire)
Aug-22-23 08:00AM	Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS (Business Wire) -13.31%
Aug-21-23 08:00AM	Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS (Business Wire)
Aug-17-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.56%
Aug-03-23 04:05PM	Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results (Business Wire)
Jul-27-23 04:30PM	Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023 (Business Wire)
Jul-20-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-29-23 08:30AM	Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS (Business Wire)
Jun-22-23 04:30PM	Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-20-23 09:00AM	Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat (Business Wire) +5.00%
Jun-13-23 09:00AM	Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS (Business Wire)
Jun-12-23 08:00AM	Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients (Business Wire) -5.83%
Jun-07-23 04:30PM	Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-06-23 04:30PM	Geron to Host Virtual Investor Event on June 14, 2023 (Business Wire)
Jun-02-23 03:30PM	Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients (Business Wire) +6.51%
May-25-23 05:02PM	Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 (Business Wire)
May-18-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-11-23 10:02AM	Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 (Business Wire)
08:00AM	Geron Corporation Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-04-23 04:30PM	Geron to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-26-23 10:05AM	Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial (Business Wire)
Apr-20-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-12-23 04:40PM	Geron to Present at Upcoming Investor Conferences in April (Business Wire)
Mar-16-23 05:45PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:05PM	Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones (Business Wire)
Mar-09-23 04:30PM	Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023 (Business Wire)
Feb-16-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-23 01:19PM	10 Hot Healthcare Stocks To Buy Now (Insider Monkey)
Jan-19-23 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-23 07:30AM	Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (Business Wire)
Jan-11-23 07:30AM	Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S. (Business Wire)
Jan-10-23 04:30PM	Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million (Business Wire) +11.86%
Jan-05-23 11:15PM	Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) -22.26%
Jan-04-23 04:19PM	Geron Corporation Announces Proposed Public Offering of Common Stock (Business Wire) +32.92%
06:55AM	Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS (Business Wire)
Jan-03-23 04:30PM	Geron Announces Conference Call for Top-Line Results from IMerge Phase 3 (Business Wire)
Dec-22-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-22 11:10AM	10 Penny Stocks That Can Grow Big in 2023 (Insider Monkey)
Dec-12-22 08:00AM	Geron Reports Oral Presentation at ASH Annual Meeting Highlighting Continuous Long-Term Transfusion Independence with Imetelstat Treatment in Lower Risk MDS Patients (Business Wire)
Dec-08-22 11:30AM	Novavax (NVAX) Down 7.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-07-22 11:30AM	Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report? (Zacks)
Dec-04-22 05:19PM	TipRanks Perfect 10 List: 2 Stocks Under $5 That Are Worth Looking Into (TipRanks)
Nov-17-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-22 04:30PM	Geron to Participate in Stifel 2022 Healthcare Conference (Business Wire)
Nov-04-22 12:00AM	Geron (GERN) Q3 2022 Earnings Call Transcript (Motley Fool)
Nov-03-22 09:25AM	Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -5.58%
09:01AM	Geron Announces Presentations at Upcoming ASH Annual Meeting Including Long-term Phase 2 Data Showing Continuous Durable Transfusion Independence in Patients with Lower Risk MDS (Business Wire)
08:00AM	Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones (Business Wire)
Oct-27-22 04:30PM	Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022 (Business Wire)
Oct-25-22 06:15AM	Investing in Geron (NASDAQ:GERN) a year ago would have delivered you a 55% gain (Simply Wall St.)
Oct-24-22 09:40AM	Is Geron (GERN) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-20-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-22-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-14-22 06:43AM	Geron Corporation's (NASDAQ:GERN) Intrinsic Value Is Potentially 95% Above Its Share Price (Simply Wall St.)
Sep-08-22 04:15PM	Geron Appoints Biopharma Veteran John F. McDonald to Board of Directors (Business Wire)
Sep-01-22 04:30PM	Geron to Present at Upcoming Investor Conferences (Business Wire)
Aug-31-22 04:55PM	Top Penny Stocks for September 2022 (Investopedia) +14.78%
04:33PM	Why Geron's Shares Rose 14.78% on Wednesday (Motley Fool)
Aug-22-22 04:15PM	Geron Announces First Patient Dosed in IMproveMF Phase 1 Combination Study in Frontline Myelofibrosis (Business Wire)
09:11AM	10 Best Penny Stocks to Invest $100 (Insider Monkey)
Aug-18-22 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-12-22 11:21AM	J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023 (Zacks) +14.63%
Aug-11-22 11:00PM	Geron (GERN) Q2 2022 Earnings Call Transcript (Motley Fool) -5.53%
05:24PM	Small Caps Begin to Rebound: 10 Stocks to Buy Now (Insider Monkey)
04:05PM	Geron Corporation Reports Second Quarter 2022 Financial Results (Business Wire)
Aug-10-22 02:54PM	Allogene (ALLO) Q1 Earnings Beat, Pipeline Progressing Well (Zacks)
Aug-09-22 12:14PM	Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat (Zacks) -7.59%
12:03PM	Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data (Zacks)
Aug-04-22 04:30PM	Geron to Announce Second Quarter 2022 Financial Results on August 11, 2022 (Business Wire) +20.59%

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Farrell Elizabeth G.	Director	Aug 24 '23	Buy	2.28	6,607	15,064	7,407	Aug 24 08:52 PM
O'Farrell Elizabeth G.	Director	Aug 24 '23	Buy	2.28	6,579	15,000	26,220	Aug 24 08:52 PM
LAWLIS V BRYAN	Director	May 11 '23	Option Exercise	1.10	35,000	38,500	35,000	May 11 09:01 PM
LAWLIS V BRYAN	Director	May 11 '23	Sale	3.00	35,000	105,000	0	May 11 09:01 PM
Molineaux Susan	Director	May 01 '23	Option Exercise	1.10	35,000	38,500	35,000	May 01 09:20 PM
Molineaux Susan	Director	May 01 '23	Sale	2.48	35,000	86,800	0	May 01 09:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GERN

Geron Corp.

Upgrade your FINVIZ experience